ref-id,title,url,parent_key
L4626,Aids info document,https://aidsinfo.nih.gov/drugs/487/peginterferon-alfa-2b--hcv/136/professional,BE0002793
L5707,Uniprot P16519,https://www.uniprot.org/uniprot/P16519,BE0002124
L5710,Uniprot P29120,https://www.uniprot.org/uniprot/P29120,BE0002125
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L3734,Neoral (Cyclosporine) FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s027,050716s028lbl.pdf",BE0002362
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L8003,CYP24A1 gene - Genetics Home Reference - NIH,https://ghr.nlm.nih.gov/gene/CYP24A1,BE0002250
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L7544,"FDA label, fluvoxamine",https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021519s003lbl.pdf,BE0002638
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0004866
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0004866
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L8435,Definition of masoprocol - NCI Drug Dictionary,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/masoprocol,BE0000248
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L4784,Benzodiazepine metabolism and pharmacokinetic,http://paindr.com/wp-content/uploads/2015/10/Revised-BZD_-9-30.pdf,BE0002638
L14177,"FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf,BE0002638
L14177,"FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf,BE0003536
L14177,"FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf,BE0002363
L14177,"FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf,BE0002433
L14177,"FDA Approved Drug Products: Bortezomib for Injection, for subcutaneous or intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021602s044lbl.pdf,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L4582,"Betaxolol, Pediatric Care Solutions",https://pediatriccare.solutions.aap.org/drug.aspx?gbosid=171921,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L6505,"Fluconazole, Medsafe NZ data sheet",https://www.medsafe.govt.nz/profs/Datasheet/f/fluconazolecapmylan.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L6505,"Fluconazole, Medsafe NZ data sheet",https://www.medsafe.govt.nz/profs/Datasheet/f/fluconazolecapmylan.pdf,BE0002793
L6505,"Fluconazole, Medsafe NZ data sheet",https://www.medsafe.govt.nz/profs/Datasheet/f/fluconazolecapmylan.pdf,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L7261,FDA Approved Drug Products: Ery-Ped (erythromycin ethylsuccinate) granules for oral suspension,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf",BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L7261,FDA Approved Drug Products: Ery-Ped (erythromycin ethylsuccinate) granules for oral suspension,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf",BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L7261,FDA Approved Drug Products: Ery-Ped (erythromycin ethylsuccinate) granules for oral suspension,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf",BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L9851,Caffeine citrate injection FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20793s1lbl.pdf,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0003536
L2924,Ticlopidine Hydrochloride - Drug Summary - PDR,http://www.pdr.net/drug-summary/Ticlopidine-Hydrochloride-ticlopidine-hydrochloride-3029,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L2924,Ticlopidine Hydrochloride - Drug Summary - PDR,http://www.pdr.net/drug-summary/Ticlopidine-Hydrochloride-ticlopidine-hydrochloride-3029,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L2924,Ticlopidine Hydrochloride - Drug Summary - PDR,http://www.pdr.net/drug-summary/Ticlopidine-Hydrochloride-ticlopidine-hydrochloride-3029,BE0003549
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L8126,Citalopram FDA label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020822s042,021046s019lbl.pdf",BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L8129,Eletriptan FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021016s018lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L8132,Nelfinavir FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021503s006lbl.pdf,BE0002638
L2906,"Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table2-2,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L3326,Interactions,https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf,BE0003541
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2915,TABLETS MEVACOR® (LOVASTATIN) FDA LABEL,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019643s085lbl.pdf,BE0002638
L5296,Public presentations,https://www.lipid.org/sites/default/files/f-_wiggins_final.pdf,BE0003541
L5296,Public presentations,https://www.lipid.org/sites/default/files/f-_wiggins_final.pdf,BE0003677
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L4349,Viramune (Nevirapine) FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20636s025,20933s014lbl.pdf",BE0003549
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L2904,Indiana University - Department of Medicine Clinical Pharmacology,http://medicine.iupui.edu/clinpharm/ddis/main-table,BE0002638
L2918,Lexicomp database,http://www.wolterskluwercdi.com/,BE0002638
L4349,Viramune (Nevirapine) FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20636s025,20933s014lbl.pdf",BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L2919,Nevirapine,https://aidsinfo.nih.gov/drugs/116/nevirapine/17/professional,BE0002433
L5473,Australian Assessment Report,https://www.tga.gov.au/sites/default/files/auspar-ranolazine-180220.pdf,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L3580,Ranolazine FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021526s007lbl.pdf,BE0002638
L3580,Ranolazine FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021526s007lbl.pdf,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L2903,Cytochrome P450 2C19 by Straight Healthcare,https://www.straighthealthcare.com/cytochrome-p450-2c19.html,BE0003536
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L3326,Interactions,https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf,BE0003541
L3852,NCI/NIH,https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C47598&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null,BE0002638
L14153,FDA Approved Drug Products: Agrylin (anagrelide) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020333s026lbl.pdf,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L5530,Researchgate publications,https://www.researchgate.net/publication/257614687_Chemical_stability-indicating_HPLC_study_of_fixed-dosage_combination_containing_metoprolol_tartrate_and_hydrochlorothiazide,BE0002638
L2914,Get to Know an Enzyme: CYP3A4 Substrates,https://www.pharmacytimes.com/publications/issue/2008/2008-09/2008-09-8687,BE0002638
L10256,Supercyp table,http://bioinformatics.charite.de/supercyp/index.php?site=get_drug_interaction,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L10544,"FDA label, topiramate",https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020505s057_020844s048lbl.pdf,BE0003536
L3791,Topamax (Topiramate) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020844s041lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L3810,Monograph,https://pdf.hres.ca/dpd_pm/00039966.PDF,BE0002638
L3811,Cyclocort monograph,https://ca.gsk.com/media/1187406/cyclocort.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L8330,STRATTERA (atomoxetine HCl) - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021411s018lbl.pdf,BE0003536
L5695,PMC,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683610/,BE0002638
L8312,"Prescriber's digital reference, Marcaine with Epinephrine-bipuvacaine-hydrochloride",https://www.pdr.net/drug-summary/Marcaine-Marcaine-with-Epinephrine-bupivacaine-hydrochloride----bupivacaine-hydrochloride-epinephrine-1700,BE0002363
L177,Link,http://www.pharmgkb.org/pathway/PA155028030,BE0004477
L177,Link,http://www.pharmgkb.org/pathway/PA155028030,BE0004780
L2902,CYP2A6 cytochrome P450 family 2 subfamily A member 6 [ Homo sapiens (human) ],https://www.ncbi.nlm.nih.gov/gene/1548,BE0003336
L3326,Interactions,https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf,BE0003541
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L8288,IRESSA (gefitinib) tablets for oral use - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdf,BE0002363
L171,Link,https://www.pharmgkb.org/pathway/PA152325160,BE0003543
L171,Link,https://www.pharmgkb.org/pathway/PA152325160,BE0002793
L171,Link,https://www.pharmgkb.org/pathway/PA152325160,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L4640,Up to Date: Floxuridine,http://uptodatefree.com/topic/floxuridine-drug-information,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L8174,Opioid Metabolism and Effects of Cytochrome P450,https://watermark.silverchair.com/10-suppl_1-S20.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAm4wggJqBgkqhkiG9w0BBwagggJbMIICVwIBADCCAlAGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM3P717upZvwRrCHzhAgEQgIICIUV8V0_1BDbWmW8s1ojPqcCrNNrisap3Ubc8wwOpzvvTTRTYkF50Ylq4DZjirW_ygB8kbr15zzBNHpZSnDhjx993jMJdXHl2mAy9QwjP3CXgbzG_909Xwn8dwNOVokYT3zkIqP4d-TQHQEcI7BntlSZeaYLs3YoHUPBUe7gWY8GS8CeU3BG9nzAltOjHHd_eeRqm8VmmTskQ8-nc58dItL7lWji20_W3rtDduM959MGYJgcqKs0kV1Dc_C44lzmbHGrZv3XinDVMEhddUlDeR13d7tuarwyK_bVa5x9NrJN88fMCAvmyCSYHv6TJadBITpGXAnmlrEb-ms471oTfS4oAPlDZtAXZebW8tWlIyuIdAHbr6bbA4fYDK3-j0oVa8oITyKlpJn9bl_uLpDplUhCPHnujLBJUXETzIijxE3InxVhYimHe1lj-8aoWEZPlP6CjnxcTpLGsPK5zWJaBwwH6hHkNH3ZXHVueE42tkx9zYqOWA6kKFWgYg2G2DpMAOcfdVoODRsOWT2YebJdRWNlI5erBuq_Bygal9Lf6I9mOtS52G4He-WHPuINB3i4b4uCFIVH8lQCMqc3Iv9BC20vzOo4I-koErjTivfKgGmJsCHZ1lLtqt4Ajpj0_bzfjl6VN2jEE3IxeBKTdTl3mRHpBVx6DhBhOMHPtDgbVnfekWHd4KK56DWTUcETZBNrOVHB-e0aiudCdyFtWtsM_GetJ,BE0003549
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L8327,SYMBYAX (olanzapine and fluoxetine HCl capsules) - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21520_symbyax_lbl.pdf,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L8177,Co-Administration of the CYP3A4 Inhibitor Diltiazem Counteracts Mitotane-Induced Clearance of Glucocorticoids and Antihypertensives in a Patient with Adrenocortical Carcinoma,https://journals.aace.com/doi/pdf/10.4158/EP15686.CR,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0003612
L9767,Clobazam FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202067s000lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L8291,"Clozapine Therapy and CYP2D6, CYP1A2, and CYP3A4 Genotypes",https://www.ncbi.nlm.nih.gov/books/NBK367795/,BE0002363
L8291,"Clozapine Therapy and CYP2D6, CYP1A2, and CYP3A4 Genotypes",https://www.ncbi.nlm.nih.gov/books/NBK367795/,BE0002638
L7760,Levonorgestrel FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021998lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L6727,Timolol maleate tablet,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=57c62928-63d8-4505-9b9e-c085a3a12c95,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L2906,"Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table2-2,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L9416,FDA Approved Drug Products: Phenylephrine Solution for Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf,BE0002198
L9410,FDA Approved Drug Products: Phenylephrine Intravenous Injection (Ready to Use),https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212909s000lbl.pdf,BE0002198
L9416,FDA Approved Drug Products: Phenylephrine Solution for Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204300lbl.pdf,BE0002196
L9410,FDA Approved Drug Products: Phenylephrine Intravenous Injection (Ready to Use),https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212909s000lbl.pdf,BE0002196
L5662,CYP3A5 cytochrome P450 family 3 subfamily A member 5 [ Homo sapiens (human) ],https://www.ncbi.nlm.nih.gov/gene/1577,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002887
L10190,Griseofulvin drug summary,https://www.pdr.net/drug-summary/Gris-PEG-griseofulvin-934,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L6769,Eszopiclone FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021476s030lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L4265,FDA Approved Drug Products: XANAX (Alprazolam) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018276s052lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L3994,Cleveland clinic,http://portals.clevelandclinic.org/portals/66/PDF/techbriefs/TB_GeneticTestOfCytochromeP4502C19ForDrugMetabolism.pdf,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002887
L3863,Academic disertation,https://pdfs.semanticscholar.org/dc99/4682bd504ab29f1c7075b9d769eb4ac4a9ce.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002433
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L7108,QUALAQUIN® quinine sulfate - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021799s008lbl.pdf,BE0002887
L4118,PDR INTERACTIONS QUININE,http://www.pdr.net/drug-summary/Qualaquin-quinine-sulfate-828,BE0003536
L7108,QUALAQUIN® quinine sulfate - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021799s008lbl.pdf,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L3607,FDA Approved Drug Products: Qualaquin ((quinine sulfate) Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021799s023lbl.pdf,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002887
L6301,Singulair (montelukast sodium) US FDA Label 2019,https://www.merck.com/product/usa/pi_circulars/s/singulair/singulair_pi.pdf,BE0002887
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0003536
L7874,Fluoxetine Metabolism Pathway,http://smpdb.ca/view/SMP0000646,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L10244,Fluoxetine FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L4558,"PharmGKB: Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics Overview",https://www.pharmgkb.org/pathway/PA165859361,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L7529,Pharm KGB Very Important Pharmacogene: CYP2D6,https://www.pharmgkb.org/vip/PA166170264,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0003536
L8210,NORVIR (ritonavir) - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209512lbl.pdf,BE0003549
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0003549
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L3326,Interactions,https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf,BE0009758
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L81,Source,http://www.currentseparations.com/issues/20-3/20-3d.pdf,BE0002363
L14363,FDA Approved Drug Products: Neudexta Dextromethorphan Hydrobromide and Quinidine Sulfate Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021879s014lbl.pdf,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L174,Link,https://www.pharmgkb.org/pathway/PA150642262,BE0002390
L174,Link,https://www.pharmgkb.org/pathway/PA150642262,BE0001184
L9218,FDA Approved Drugs Products: Albendazole Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020666s012lbl.pdf,BE0003543
L9218,FDA Approved Drugs Products: Albendazole Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020666s012lbl.pdf,BE0002433
L8318,Caspofungin EMA label,https://www.ema.europa.eu/en/documents/product-information/caspofungin-accord-epar-product-information_en.pdf,BE0002638
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0000818
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0004778
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0004779
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0001075
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0002390
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0000814
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0000807
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0001184
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L4506,LERCANIDIPINE - Australian Prescribing Information,http://www.medicines.org.au/files/txplerca.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L164,Source,http://herkules.oulu.fi/isbn9514259009/html/index.html,BE0003549
L4536,NCBI Cytochrome P450 CYP2C8 Profile,https://www.ncbi.nlm.nih.gov/gene/1558,BE0002887
L8438,VIOXX® (rofecoxib tablets and oral suspension) - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21647_vioxx_lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L7532,The Inhibitory Effect of Amoxapine on Cytochrome P450 Enzyme Activity in Human Liver Microsomes,https://www.jstage.jst.go.jp/article/sujms1989/16/4/16_4_329/_article/-char/en,BE0002363
L172,Link,https://www.pharmgkb.org/pathway/PA150653776,BE0004473
L172,Link,https://www.pharmgkb.org/pathway/PA150653776,BE0000374
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L9404,Lamictal FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020241s060,020764s053,022251s024lbl.pdf",BE0009758
L9404,Lamictal FDA Label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020241s060,020764s053,022251s024lbl.pdf",BE0000330
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L9680,Health Canada Product Monograph: Hydroxyzine HCl oral capsules,https://www.aapharma.ca/downloads/en/PIL/2018/Hydroxyzine-Pr_Info_Mono-ENG-Jul_09_2018.pdf,BE0002638
L9680,Health Canada Product Monograph: Hydroxyzine HCl oral capsules,https://www.aapharma.ca/downloads/en/PIL/2018/Hydroxyzine-Pr_Info_Mono-ENG-Jul_09_2018.pdf,BE0002362
L9764,FDA table of interactions,https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L9758,FDA interactions table,https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#cypEnzymes,BE0002638
L1334,Tegretol FDA label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/016608s101,018281s048lbl.pdf",BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L4596,CYP table,https://drug-interactions.medicine.iu.edu/Clinical-Table.aspx,BE0002433
L2904,Indiana University - Department of Medicine Clinical Pharmacology,http://medicine.iupui.edu/clinpharm/ddis/main-table,BE0003536
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0003536
L7195,"Pharm KGB, carbamazepine pathway, pharmacokinetics",https://www.pharmgkb.org/pathway/PA165817070,BE0003549
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L7195,"Pharm KGB, carbamazepine pathway, pharmacokinetics",https://www.pharmgkb.org/pathway/PA165817070,BE0003679
L3326,Interactions,https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf,BE0003541
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L3868,FDA reports,https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM421134.pdf,BE0002887
L7294,Cardura XL label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021269s011lbl.pdf,BE0003536
L7294,Cardura XL label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021269s011lbl.pdf,BE0002363
L4870,Dailymed,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ed04255-7d9c-464c-bfa6-c355755862d8,BE0002638
L7294,Cardura XL label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021269s011lbl.pdf,BE0002638
L7297,Cardura monograph,https://www.pfizer.ca/sites/g/files/g10050796/f/201710/CARDURA_PM_Eng_201486_4Apr2017.pdf,BE0002638
L7297,Cardura monograph,https://www.pfizer.ca/sites/g/files/g10050796/f/201710/CARDURA_PM_Eng_201486_4Apr2017.pdf,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L10235,Abbvie: Venetoclax,https://www.abbvie.ca/content/dam/abbviecorp/ca/en/docs/VENCLEXTA_PM_EN.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L7219,Bisoprolol monograph,https://www.sandoz.ca/sites/www.sandoz.ca/files/Bisoprolol_TAB_Monograph.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002887
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L3517,Mycobutin (Rifabutin) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050689s016lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L4397,GLEEVEC (imatinib mesylate) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L8342,Fluphenazine - StatPearls - NCBI Bookshelf,https://www.ncbi.nlm.nih.gov/books/NBK459194/,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L81,Source,http://www.currentseparations.com/issues/20-3/20-3d.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L8045,"Gene cards, CYP2A13",https://www.genecards.org/cgi-bin/carddisp.pl?gene=CYP2A13,BE0003534
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L9764,FDA table of interactions,https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L9764,FDA table of interactions,https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L3326,Interactions,https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf,BE0003541
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L80,Website,http://www.ihop-net.org/UniPub/iHOP/,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L8357,Xalatan FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020597s044lbl.pdf,BE0009756
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L3484,Trazodone,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018207s032lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L3837,CRDD,http://crdd.osdd.net/raghava/metapred/SupplemantryData.doc,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L8099,niLUTAmide - Cancer Care Ontario,https://www.cancercareontario.ca/sites/ccocancercare/files/nilutamide.pdf,BE0003536
L8102,Nilutamide Monograph - BC Cancer,http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Nilutamide_monograph_1Aug07.pdf,BE0003536
L4361,Medicines UK document,https://www.medicines.org.uk/emc/product/4289/smpc#PHARMACOKINETIC_PROPS,BE0002089
L4361,Medicines UK document,https://www.medicines.org.uk/emc/product/4289/smpc#PHARMACOKINETIC_PROPS,BE0004909
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L4066,Health Canada Approved Drug Products: Manerix (Moclobemide) tablets,https://pdf.hres.ca/dpd_pm/00032713.PDF,BE0002363
L8105,Thioridazine Therapy and CYP2D6 Genotypes,https://www.ncbi.nlm.nih.gov/books/NBK424018/,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L3702,Cafergot (Ergotamine tartrate and Caffeine) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/9000s22s23lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L3766,Delavirdine FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020705s018lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L13919,FDA Approved Drug Products: Apomorphine Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021264s018lbl.pdf,BE0003549
L13919,FDA Approved Drug Products: Apomorphine Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021264s018lbl.pdf,BE0002887
L13919,FDA Approved Drug Products: Apomorphine Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021264s018lbl.pdf,BE0002638
L13919,FDA Approved Drug Products: Apomorphine Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021264s018lbl.pdf,BE0002362
L13919,FDA Approved Drug Products: Apomorphine Subcutaneous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021264s018lbl.pdf,BE0009758
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L178,Link,https://www.pharmgkb.org/pathway/PA155028030,BE0004477
L178,Link,https://www.pharmgkb.org/pathway/PA155028030,BE0004780
L178,Link,https://www.pharmgkb.org/pathway/PA155028030,BE0003106
L178,Link,https://www.pharmgkb.org/pathway/PA155028030,BE0003281
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L165,Source,http://www.healthscout.com/rxdetail/68/110/8/main.html,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L8108,Esomeprazole Therapy and CYP2C19 Genotype,https://www.ncbi.nlm.nih.gov/books/NBK100896/,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L4606,FDA Approved Drug Products: ZYFLO CR (zileuton) extended-release tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022052s005lbl.pdf,BE0002638
L9758,FDA interactions table,https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#cypEnzymes,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L9758,FDA interactions table,https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#cypEnzymes,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L8279,Clopidogrel Therapy and CYP2C19 Genotype,https://www.ncbi.nlm.nih.gov/books/NBK84114/,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L173,Link,https://www.pharmgkb.org/pathway/PA2029,BE0002180
L7880,FDA Approved Drug Products: Augmentin Amoxicillin and Clavulanate Oral Tablets and Suspension,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf",BE0009711
L7904,"Augmentin IV, Medicines UK",https://www.medicines.org.uk/emc/medicine/2025,BE0009711
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L8627,FDA Approved Drugs: Oxcarbazepine,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021014s043lbl.pdf,BE0003536
L8630,DPD Approved Drugs: Oxcarbazepine,https://pdf.hres.ca/dpd_pm/00048247.PDF,BE0003536
L8633,MedSafe NZ: Oxcarbazepine,https://www.medsafe.govt.nz/profs/Datasheet/t/Trileptaltab.pdf,BE0003536
L8627,FDA Approved Drugs: Oxcarbazepine,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021014s043lbl.pdf,BE0002638
L8630,DPD Approved Drugs: Oxcarbazepine,https://pdf.hres.ca/dpd_pm/00048247.PDF,BE0002638
L8633,MedSafe NZ: Oxcarbazepine,https://www.medsafe.govt.nz/profs/Datasheet/t/Trileptaltab.pdf,BE0002638
L3971,Trileptal (Oxcarbazepine) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021014s036lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L8627,FDA Approved Drugs: Oxcarbazepine,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021014s043lbl.pdf,BE0002362
L8630,DPD Approved Drugs: Oxcarbazepine,https://pdf.hres.ca/dpd_pm/00048247.PDF,BE0002362
L8633,MedSafe NZ: Oxcarbazepine,https://www.medsafe.govt.nz/profs/Datasheet/t/Trileptaltab.pdf,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L11485,FDA Approved Products: Estrace (Estradiol) oral tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf",BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003543
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L4624,primidone - Drug Summary,https://www.pdr.net/drug-summary/Mysoline-primidone-775,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L11398,FDA approved products: Mobic (meloxicam) oral tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020938s024s025,021530s014s015lbl.pdf",BE0002793
L11398,FDA approved products: Mobic (meloxicam) oral tablets,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020938s024s025,021530s014s015lbl.pdf",BE0002638
L8006,Cancer.gov CTEP document,https://ctep.cancer.gov/protocoldevelopment/docs/cyp2c89.doc,BE0002887
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L3826,Gene labs,http://genelabs.com/drugsdb/details/ethynodiol-diacetate/,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L8282,Diazepam Therapy and CYP2C19 Genotype,https://www.ncbi.nlm.nih.gov/books/NBK379740/,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L3576,Mifeprex (Mifepristone) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L4651,PDR,https://www.pdr.net/drug-summary/Korlym-mifepristone-2928.2022,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L13802,FDA Approved Drug Products: Lamprene (clofazimine) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf,BE0002362
L13802,FDA Approved Drug Products: Lamprene (clofazimine) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf,BE0002887
L13802,FDA Approved Drug Products: Lamprene (clofazimine) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019500s014lbl.pdf,BE0002363
L3841,NCI/NIH,https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C47537&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L8009,BC Cancer website,http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Dacarbazine_monograph_1June2013_formatted.pdf,BE0003543
L9065,FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf,BE0002793
L9065,FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf,BE0002433
L9065,FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf,BE0002638
L9065,FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf,BE0002887
L9065,FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002363
L9065,FDA Approved Drug Products: Lamisil Terbinafine Hydrochloride Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020539s033lbl.pdf,BE0002363
L8012,"Bayer monograph, Levitra",https://www.bayer.ca/omr/online/levitra-pm-en.pdf,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L6991,Ranitidine drug summary,https://www.pdr.net/drug-summary/Ranitidine-Hydrochloride-Capsules-and-Tablets-ranitidine-hydrochloride-2965,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L10818,FDA Approved Drug Products: ZANTAC (ranitidine hydrochloride) injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019090s053,019593s042lbl.pdf",BE0000426
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L3850,NCI/NIH,https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C72818&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null,BE0002638
L4539,Electronic Medicines Compendium: Loteprednol etabonate Monograph,https://www.medicines.org.uk/emc/product/6212,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L3858,NCI/NIH,https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C47705&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L6892,"Allergen monograph, Bimatoprost",https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/lumigan-rc-pm-2016-05-11_e.pdf,BE0002638
L6892,"Allergen monograph, Bimatoprost",https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/lumigan-rc-pm-2016-05-11_e.pdf,BE0002362
L8015,Tiagabine FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020646s017lbl.pdf,BE0002638
L3326,Interactions,https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf,BE0003541
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L12342,FDA Approved Products: Numbrino (cocaine hydrochloride) nasal solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209575s000lbl.pdf,BE0002638
L12342,FDA Approved Products: Numbrino (cocaine hydrochloride) nasal solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209575s000lbl.pdf,BE0002180
L12342,FDA Approved Products: Numbrino (cocaine hydrochloride) nasal solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209575s000lbl.pdf,BE0002705
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L3326,Interactions,https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf,BE0003541
L8018,Tinidazole FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021618s003lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002887
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L4596,CYP table,https://drug-interactions.medicine.iu.edu/Clinical-Table.aspx,BE0002793
L9269,FDA Approved Drug Products: Almotriptan Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021001s015lbl.pdf,BE0002638
L9269,FDA Approved Drug Products: Almotriptan Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021001s015lbl.pdf,BE0002363
L9269,FDA Approved Drug Products: Almotriptan Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021001s015lbl.pdf,BE0002198
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L8021,"FDA label, cyclobenzaprine",https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/017821s045lbl.pdf,BE0002363
L11139,"FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf,BE0002433
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L3326,Interactions,https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf,BE0003541
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L11545,FDA Approved Drug Products: Wixela Inhub Fluticasone and Salmeterol Inhalation Powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208891Orig1s000lbl.pdf,BE0002638
L11548,FDA Approved Drug Products: Serevent Diskus Salmeterol Inhalation Powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020692s047lbl.pdf,BE0002638
L11551,FDA Approved Drug Products: Airduo Respiclick Fluticasone and Salmeterol Inhalation Powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208799s001lbl.pdf,BE0002638
L11557,FDA Approved Drug Products: Advair Diskus Fluticasone and Salmeterol Inhalation Powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021077s061lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L8024,Fluvestrant FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021344s015lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002793
L4515,"UMN Interaction Table, CYP450",https://www.d.umn.edu/~jfitzake/Lectures/DMED/TAA/Q_A/CYP450InteractionTable.htm,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L7913,FDA Label: Hydrocodone Tab ER,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206627s007s008lbl.pdf,BE0003549
L7913,FDA Label: Hydrocodone Tab ER,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206627s007s008lbl.pdf,BE0003536
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0001075
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0000818
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0004778
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0004779
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0000814
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0000807
L175,Link,https://www.pharmgkb.org/pathway/PA150642262#,BE0001184
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L3588,telmisartan - Drug Summary,http://www.pdr.net/drug-summary/Micardis-telmisartan-1320,BE0003536
L4575,Alosteron,https://www.drugs.com/ppa/alosetron.html,BE0002433
L8027,Alosetron FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21107s5lbl.pdf,BE0002638
L8324,LOTRONEX (alosetron hydrochloride) Tablets - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21107lbl.pdf,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L3583,Telithromycin FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021144s013lbl.pdf,BE0002638
L10986,FDA Approved Drug Products: Perforomist® inhalation solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf,BE0002363
L10986,FDA Approved Drug Products: Perforomist® inhalation solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf,BE0003536
L10986,FDA Approved Drug Products: Perforomist® inhalation solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf,BE0002793
L10986,FDA Approved Drug Products: Perforomist® inhalation solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf,BE0003336
L10986,FDA Approved Drug Products: Perforomist® inhalation solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf,BE0008629
L10986,FDA Approved Drug Products: Perforomist® inhalation solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf,BE0003682
L10986,FDA Approved Drug Products: Perforomist® inhalation solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf,BE0003538
L10986,FDA Approved Drug Products: Perforomist® inhalation solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf,BE0003679
L10986,FDA Approved Drug Products: Perforomist® inhalation solution,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022007s015lbl.pdf,BE0004696
L8030,"Gene card, CYP19A1",https://www.genecards.org/cgi-bin/carddisp.pl?gene=CYP19A1,BE0002090
L8036,"FDA label, Exemestane",https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020753s009s011s012lbl.pdf,BE0002090
L11214,FDA Approved Drug Products: Imuran Azathioprine Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016324s039lbl.pdf,BE0000077
L11214,FDA Approved Drug Products: Imuran Azathioprine Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016324s039lbl.pdf,BE0009809
L11214,FDA Approved Drug Products: Imuran Azathioprine Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016324s039lbl.pdf,BE0000987
L179,Link,https://www.pharmgkb.org/pathway/PA2040,BE0002281
L179,Link,https://www.pharmgkb.org/pathway/PA2040,BE0002189
L179,Link,https://www.pharmgkb.org/pathway/PA2040,BE0000807
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L8354,Hydroxyurea - National Toxicology Program - NIH,https://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/hydroxyurea_508.pdf,BE0002363
L11623,FDA Approved Drug Products: Femara Letrozole Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020726s035lbl.pdf,BE0002090
L11626,FDA Approved Drug Products: Kisquali Femara Co-Pack Letrozole and Ribociclib Succinate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209935s006lbl.pdf,BE0002090
L11623,FDA Approved Drug Products: Femara Letrozole Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020726s035lbl.pdf,BE0002638
L11626,FDA Approved Drug Products: Kisquali Femara Co-Pack Letrozole and Ribociclib Succinate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209935s006lbl.pdf,BE0002638
L11623,FDA Approved Drug Products: Femara Letrozole Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020726s035lbl.pdf,BE0003336
L11626,FDA Approved Drug Products: Kisquali Femara Co-Pack Letrozole and Ribociclib Succinate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209935s006lbl.pdf,BE0003336
L11623,FDA Approved Drug Products: Femara Letrozole Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020726s035lbl.pdf,BE0003536
L11626,FDA Approved Drug Products: Kisquali Femara Co-Pack Letrozole and Ribociclib Succinate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209935s006lbl.pdf,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L11277,FDA Approved Drug Products: Intuniv Guanfacine Hydrochloride Extended Release Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022037s019lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L8171,Felodipine - LiverTox - NIH,https://livertox.nih.gov/Felodipine.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L179,Link,https://www.pharmgkb.org/pathway/PA2040,BE0003539
L8588,FDA Approved Drug Products: Fenofibrate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s010lbl.pdf,BE0002887
L8591,FDA Approved Drug Products: Fenofibrate Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021612s020lbl.pdf,BE0002887
L8588,FDA Approved Drug Products: Fenofibrate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s010lbl.pdf,BE0003536
L8591,FDA Approved Drug Products: Fenofibrate Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021612s020lbl.pdf,BE0003536
L8588,FDA Approved Drug Products: Fenofibrate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022118s010lbl.pdf,BE0003336
L8591,FDA Approved Drug Products: Fenofibrate Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021612s020lbl.pdf,BE0003336
L4031,"The Effect of Cytochrome P450 Metabolism on Drug Response, Interactions, and Adverse Effects",https://www.aafp.org/afp/2007/0801/p391.html,BE0002433
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L4519,Rifampicin,http://bioinformatics.charite.de/transformer/index.php?site=fullinfo,BE0003536
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0003612
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002362
L2681,Kegg,http://www.genome.jp/dbget-bin/www_bget?dr:D02268,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L9743,"FDA Approved Drug Products: Talicia Amoxicillin, Omeprazole, and Rifabutin Oral Delayed Release Capsules",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213004lbl.pdf,BE0001426
L11650,FDA Approved Drug Products: Augmentin XR Amoxicillin and Clavulanate Oral Extended Release Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050785s015lbl.pdf,BE0001426
L7880,FDA Approved Drug Products: Augmentin Amoxicillin and Clavulanate Oral Tablets and Suspension,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050564s053s055,050575s040s042,050597s047s049,050720s026s028,050725s028s030,050726s022s024lbl.pdf",BE0001426
L11653,FDA Approved Drug Products: Amoxicillin and Clavulanate Oral Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/065162s021lbl.pdf,BE0001426
L11656,FDA Approved Drug Products: Amoxicillin Oral Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/065119s020lbl.pdf,BE0001426
L11659,FDA Approved Drug Products: Amoxicillin Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/065056s017lbl.pdf,BE0001426
L8648,Ditropan XL FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020897s037lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L7535,Physician Guidelines: Drugs Metabolized by Cytochrome P450’s,http://ildcare.eu/Downloads/artseninfo/Drugs_metabolized_by_CYP450s.pdf,BE0002363
L3424,Atazanavir FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf,BE0002638
L3424,Atazanavir FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf,BE0003541
L3424,Atazanavir FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf,BE0002887
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L3846,Atorvastatin FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020702s057lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0003612
L13616,FDA Approved Drug Products: Sabril (vigabatrin) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020427s021,022006s023lbl.pdf",BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002363
L9022,"Zoloft, PDR",https://www.pdr.net/drug-summary/Zoloft-sertraline-hydrochloride-474.3608,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L9022,"Zoloft, PDR",https://www.pdr.net/drug-summary/Zoloft-sertraline-hydrochloride-474.3608,BE0002793
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0003549
L9188,Sertraline pathway,https://www.pharmgkb.org/pathway/PA166181117,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L14021,FDA Approved Drug Products: Oravig (miconazole) buccal tablet,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022404s005lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0003549
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L8267,ADALAT® XL® (Nifedipine extended-release tablets) Product Monograph,https://www.bayer.ca/omr/online/adalat-xl-pm-eng.pdf,BE0002433
L8267,ADALAT® XL® (Nifedipine extended-release tablets) Product Monograph,https://www.bayer.ca/omr/online/adalat-xl-pm-eng.pdf,BE0003336
L166,Drug Interactions: Cytochrome P450 Drug Interaction Table,http://medicine.iupui.edu/clinpharm/ddis/table.aspx,BE0002638
L2908,Electronic Medicines Compendium Amiodarone 100mg Tablets,https://www.medicines.org.uk/emc/product/6019/smpc,BE0002638
L3561,FDA Approved Drug Products: Cordarone (amiodarone HCl) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018972s042lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L3561,FDA Approved Drug Products: Cordarone (amiodarone HCl) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018972s042lbl.pdf,BE0002887
L166,Drug Interactions: Cytochrome P450 Drug Interaction Table,http://medicine.iupui.edu/clinpharm/ddis/table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002363
L166,Drug Interactions: Cytochrome P450 Drug Interaction Table,http://medicine.iupui.edu/clinpharm/ddis/table.aspx,BE0002793
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002793
L166,Drug Interactions: Cytochrome P450 Drug Interaction Table,http://medicine.iupui.edu/clinpharm/ddis/table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L3561,FDA Approved Drug Products: Cordarone (amiodarone HCl) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018972s042lbl.pdf,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L6256,Avodart (dutasteride capsules) - Product Monograph,https://ca.gsk.com/media/588688/avodart.pdf,BE0002362
L4559,Bicalutamide,http://www.pdr.net/drug-summary/Casodex-bicalutamide-2161,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L3856,NCI/NIH,https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C47684&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null,BE0002638
L3884,University of Liverpool,https://hep-druginteractions.org/interactions/1205/all,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002887
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L11416,FDA Approved Drug Products: Actos (pioglitazone) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s049lbl.pdf,BE0003543
L8180,Carvedilol Therapy and CYP2D6 Genotype,https://www.ncbi.nlm.nih.gov/books/NBK518573/,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L8180,Carvedilol Therapy and CYP2D6 Genotype,https://www.ncbi.nlm.nih.gov/books/NBK518573/,BE0002363
L8180,Carvedilol Therapy and CYP2D6 Genotype,https://www.ncbi.nlm.nih.gov/books/NBK518573/,BE0002638
L8180,Carvedilol Therapy and CYP2D6 Genotype,https://www.ncbi.nlm.nih.gov/books/NBK518573/,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L4604,Get to Know an Enzyme: CYP1A2,https://www.pharmacytimes.com/publications/issue/2007/2007-11/2007-11-8279,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L8315,Health Canada Product Monograph: Bupropion sustained-release tablets,https://pdf.hres.ca/dpd_pm/00018678.PDF,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L92,Link,http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Flutamide.htm,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L4066,Health Canada Approved Drug Products: Manerix (Moclobemide) tablets,https://pdf.hres.ca/dpd_pm/00032713.PDF,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002887
L4424,PHENOBARBITAL SODIUM INJECTION Prescribing Information - Sandoz Canada,https://www.sandoz.ca/sites/www.sandoz.ca/files/Phenobarbital%20Product%20Monograph.pdf,BE0002638
L3326,Interactions,https://hivclinic.ca/archive/main/drugs_interact_files/anticonvulsant-int.pdf,BE0003541
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L8513,FDA Approved Drug Products: Lexapro (escitalopram) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021323s051,021365s036lbl.pdf",BE0002638
L8516,DPD Approved Drugs: Escitalopram,https://www.lundbeck.com/upload/ca/en/files/pdf/pm/Cipralex%20JUN2018_PM_E_clean.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002363
L8513,FDA Approved Drug Products: Lexapro (escitalopram) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021323s051,021365s036lbl.pdf",BE0002363
L8516,DPD Approved Drugs: Escitalopram,https://www.lundbeck.com/upload/ca/en/files/pdf/pm/Cipralex%20JUN2018_PM_E_clean.pdf,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L8513,FDA Approved Drug Products: Lexapro (escitalopram) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021323s051,021365s036lbl.pdf",BE0003536
L8516,DPD Approved Drugs: Escitalopram,https://www.lundbeck.com/upload/ca/en/files/pdf/pm/Cipralex%20JUN2018_PM_E_clean.pdf,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L12135,Health Canada Approved Drug Products: Domperidone Oral Tablets,https://pdf.hres.ca/dpd_pm/00029814.PDF,BE0002638
L8396,Domperidone 10mg Tablets - Summary of Product Characteristics - eMC,https://www.medicines.org.uk/emc/product/556/smpc,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L8042,Australian Government: Public Assessment Report for Brinzolamide/ Timolol Maleate,https://www.tga.gov.au/sites/default/files/auspar-timolol.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L6865,IMOVANE (Zopiclone) Product Monograph,http://products.sanofi.ca/en/imovane.pdf,BE0002638
L6865,IMOVANE (Zopiclone) Product Monograph,http://products.sanofi.ca/en/imovane.pdf,BE0002887
L8195,Bromocriptine Monograph - BC Cancer,http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Bromocriptine_monograph_1Nov07.pdf,BE0002638
L4734,Parlodel (bromocriptine mesylate) - FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017962s065s068lbl.pdf,BE0002638
L3995,Priftin (Rifapentine) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021024s009lbl.pdf,BE0002638
L8033,FDA Approved Drug Products: Mitoxantrone,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019297s035lbl.pdf,BE0003533
L8378,Lomustine Drug Monograph - BC Cancer,http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Lomustine_monograph.pdf,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L8198,BIAXIN (clarithromycin) - Drug Monograph,https://www.mylan.ca/-/media/mylanca/documents/english/product%20pdf/biaxin-pm-2016-05-31.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L8863,FDA Approved Drug Products: Arimidex (anastrozole) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020541s031lbl.pdf,BE0002638
L8869,DPD Approved Drugs: Anastrozole,https://pdf.hres.ca/dpd_pm/00037304.PDF,BE0002638
L8863,FDA Approved Drug Products: Arimidex (anastrozole) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020541s031lbl.pdf,BE0002887
L8869,DPD Approved Drugs: Anastrozole,https://pdf.hres.ca/dpd_pm/00037304.PDF,BE0002887
L8863,FDA Approved Drug Products: Arimidex (anastrozole) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020541s031lbl.pdf,BE0002433
L8869,DPD Approved Drugs: Anastrozole,https://pdf.hres.ca/dpd_pm/00037304.PDF,BE0002433
L8863,FDA Approved Drug Products: Arimidex (anastrozole) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020541s031lbl.pdf,BE0002793
L8869,DPD Approved Drugs: Anastrozole,https://pdf.hres.ca/dpd_pm/00037304.PDF,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L10601,FDA Approved Drug Products: Entocort Budesonide Oral Extended Release Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021324s018lbl.pdf,BE0002638
L10604,FDA Approved Drug Products: Ortikos Budesonide Oral Extended Release Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211929s000lbl.pdf,BE0002638
L10607,FDA Approved Drug Products: Pulmicort Budesonide Inhalation Powder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021949s013lbl.pdf,BE0002638
L10613,FDA Approved Drug Products: Pulmicort Budesonide Inhalation Suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020929s052lbl.pdf,BE0002638
L10616,FDA Approved Drug Products: Rhinocort Budesonide Nasal Metered Spray,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020746Orig1s037lbl.pdf,BE0002638
L10619,FDA Approved Drug Products: Symbicort (budesonide/formoterol fumarate) inhalation aerosol,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021929s042lbl.pdf,BE0002638
L10622,FDA Approved Drug Products: Uceris Budesonide Oral Extended Release Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203634s000lbl.pdf,BE0002638
L10625,FDA Approved Drug Products: Uceris Budesonide Rectal Aerosol Foam,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205613s000lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002887
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L10184,"Dexamethasone monograph, Boehringer Ingelheim",https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Roxane/Dexamethasone/Dexamethasone%20Tablets%20Solution%20and%20Intensol.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L10710,FDA Approved Drug Products: Hemady Dexamethasone Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211379s000lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L8201,Aripiprazole Therapy and CYP2D6 Genotype,https://www.ncbi.nlm.nih.gov/books/NBK385288/,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002887
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L163,The P450 Program,http://mhc.com/Cytochromes/,BE0003536
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L4574,"PDR, Anafranil",http://www.pdr.net/drug-summary/Anafranil-clomipramine-hydrochloride-678,BE0002433
L163,The P450 Program,http://mhc.com/Cytochromes/,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L4141,Tykerb (Lapatinib) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf,BE0002638
L4141,Tykerb (Lapatinib) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf,BE0002362
L2938,Get to know an Enzyme: CYP2C8,http://www.hanstenandhorn.com/hh-article-December-2011.pdf,BE0002887
L4141,Tykerb (Lapatinib) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf,BE0002887
L4141,Tykerb (Lapatinib) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf,BE0003536
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L9227,FDA Approved Drug Products: Prezista (darunavir) oral tablets/suspension,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf",BE0002638
L9227,FDA Approved Drug Products: Prezista (darunavir) oral tablets/suspension,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf",BE0002363
L3954,Invega (Paliperidone) FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021999s018lbl.pdf,BE0002638
L4137,Invega Trinza (Paliperidone palmitate) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207946s000lbl.pdf,BE0002638
L4137,Invega Trinza (Paliperidone palmitate) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207946s000lbl.pdf,BE0002363
L3954,Invega (Paliperidone) FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021999s018lbl.pdf,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L8138,Colchicine FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022352s017lbl.pdf,BE0002638
L10187,Amprenavir FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022116s023_21548-s39lbl.pdf,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002793
L3141,Fosphenytoin sodium - Drug Summary - Prescribers Digital Reference - Drug Interactions,http://www.pdr.net/drug-summary/Cerebyx-fosphenytoin-sodium-3925,BE0002433
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003536
L3136,PDR,http://www.pdr.net/drug-summary/Necon-ethinyl-estradiol-norethindrone----mestranol-norethindrone-2049,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L10205,Quinupristin FDA label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050748s008,050747s008lbl.pdf",BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L10247,"EMA assessment, gingko biloba",https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-ginkgo-biloba-l-folium_en.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L8138,Colchicine FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022352s017lbl.pdf,BE0002638
L8192,"Pharmacology review, FDA",https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204820Orig1s000PharmR.pdf,BE0002638
L7997,Angeliq EU label,http://mri.cts-mrp.eu/download/NL_H_0380_001_FinalSPC.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L10199,Zocor PI monograph,https://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf,BE0002638
L1162,Empowerpharmacy,https://www.empowerpharmacy.com/drugs/testosterone-propionate-injection.html,BE0004887
L1162,Empowerpharmacy,https://www.empowerpharmacy.com/drugs/testosterone-propionate-injection.html,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L4594,Theophylline metabolic pathway,https://www.pharmgkb.org/pathway/PA165958541,BE0002433
L8306,Lectopam monograph,https://www.rochecanada.com/PMs/Lectopam/Lectopam_PM_E.pdf,BE0002433
L4564,PubChem: Liotrix Profile,https://pubchem.ncbi.nlm.nih.gov/compound/Liotrix#section=Top,BE0002887
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L7511,FDA Approved Drug Products: Solifenacin Succinate Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021518s018lbl.pdf,BE0002638
L7568,FDA: Recarbrio Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf,BE0001148
L7568,FDA: Recarbrio Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf,BE0002015
L7568,FDA: Recarbrio Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf,BE0003894
L7568,FDA: Recarbrio Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf,BE0002831
L7568,FDA: Recarbrio Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf,BE0009747
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L11163,FDA Approved Drug Products: Kaletra (lopinavir/ritonavir) for oral use,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021251s058,021906s053lbl.pdf",BE0004866
L4583,Thiothixene,http://www.pdr.net/drug-summary/Thiothixene-thiothixene-2297,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L4584,"Daily Med, Genistein",https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=899ea7ce-0996-4635-9545-1e07091cf400,BE0002433
L867,Pharmaceuticals and Medical Devices Agency (PMDA): Topiroxostat review,https://www.pmda.go.jp/files/000153624.pdf,BE0002887
L867,Pharmaceuticals and Medical Devices Agency (PMDA): Topiroxostat review,https://www.pmda.go.jp/files/000153624.pdf,BE0002793
L867,Pharmaceuticals and Medical Devices Agency (PMDA): Topiroxostat review,https://www.pmda.go.jp/files/000153624.pdf,BE0003543
L867,Pharmaceuticals and Medical Devices Agency (PMDA): Topiroxostat review,https://www.pmda.go.jp/files/000153624.pdf,BE0002638
L867,Pharmaceuticals and Medical Devices Agency (PMDA): Topiroxostat review,https://www.pmda.go.jp/files/000153624.pdf,BE0003536
L1060,KEGG metabolism,http://www.genome.jp/kegg-bin/show_pathway?hsa00430,BE0002239
L1060,KEGG metabolism,http://www.genome.jp/kegg-bin/show_pathway?hsa00430,BE0002303
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L8561,3OLI: Structures Of Human Pancreatic Alpha-amylase In Complex With Acarviostatin Iv03,https://www.ncbi.nlm.nih.gov/Structure/pdb/3OLI,BE0002639
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002887
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L3817,NHS,http://www.barnsleyccg.nhs.uk/CCG%20Downloads/Members/Medicines%20management/Prescribing%20Guidelines/Prostate%20cancer%20Amber%20with%20guidance%20April%202015.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L3566,Dronedarone FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022425s010lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L7985,FDA Approved Drug Products: Nebivolol Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf,BE0002363
L4107,Tasigna® (nilotinib) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf,BE0002638
L8492,FDA Approved Drug Products: Orbactiv (oritavancin) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206334s005lbl.pdf,BE0002638
L8492,FDA Approved Drug Products: Orbactiv (oritavancin) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206334s005lbl.pdf,BE0002363
L8495,EMA Assessment Report: Orbactiv,https://www.ema.europa.eu/en/documents/assessment-report/orbactiv-epar-public-assessment-report_en.pdf,BE0002363
L2801,FDA reports,https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM602419.pdf,BE0002363
L4590,Lofexidine,https://www.drugs.com/ppa/lofexidine.html,BE0002433
L2801,FDA reports,https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM602419.pdf,BE0003536
L4160,Beleodaq (Belinostat) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf,BE0008629
L757,FDA Cross discipline team leader review,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206256Orig1s000CrossR.pdf,BE0002433
L925,EMA Product Label,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002720/WC500171813.pdf,BE0003538
L925,EMA Product Label,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002720/WC500171813.pdf,BE0001066
L925,EMA Product Label,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002720/WC500171813.pdf,BE0003645
L925,EMA Product Label,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002720/WC500171813.pdf,BE0003659
L8057,"Pretomanid briefing document, FDA",https://www.fda.gov/media/127592/download,BE0002638
L8048,"Pretomanid FDA label, August 2019",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf,BE0002638
L8048,"Pretomanid FDA label, August 2019",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212862s000lbl.pdf,BE0009325
L161,Link,http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515,BE0003609
L161,Link,http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515,BE0003606
L161,Link,http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2a87691-c9ad-4753-97a1-311fccfe6515,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L7501,"FDA label, Otezla",https://media.celgene.com/content/uploads/otezla-pi.pdf,BE0002638
L7501,"FDA label, Otezla",https://media.celgene.com/content/uploads/otezla-pi.pdf,BE0003336
L7501,"FDA label, Otezla",https://media.celgene.com/content/uploads/otezla-pi.pdf,BE0002433
L12633,FDA Approved Products: Ocaliva (obeticholic acid) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207999s003lbl.pdf,BE0002433
L10860,CAPLYTA®,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf,BE0002887
L10860,CAPLYTA®,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf,BE0002433
L10860,CAPLYTA®,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf,BE0003541
L10860,CAPLYTA®,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf,BE0003544
L10860,CAPLYTA®,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf,BE0004696
L10860,CAPLYTA®,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf,BE0000126
L10860,CAPLYTA®,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf,BE0004353
L10860,CAPLYTA®,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf,BE0000438
L10653,FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf,BE0003679
L10653,FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf,BE0003681
L10653,FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf,BE0003533
L10653,FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf,BE0003336
L10653,FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf,BE0003549
L10653,FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf,BE0003536
L10653,FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf,BE0002638
L10653,FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf,BE0002362
L10653,FDA Approved Drug Products: Xcopri Cenobamate Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf,BE0002887
L2392,Pentaerythritol tetranitrate,https://pubchem.ncbi.nlm.nih.gov/compound/pentaerythritol_tetranitrate,BE0003578
L2393,CheBi - Pentaerythritol,https://www.ebi.ac.uk/chebi/searchId.do?chebiId=25879,BE0000263
L2417,"Nitrate Reduction to Nitrite, Nitric Oxide and Ammonia by Gut Bacteria under Physiological Conditions",http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119712,BE0000263
L2395,OSHA document,https://www.osha.gov/dts/chemicalsampling/data/CH_260110.html,BE0000133
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L4507,Drugs.com Lacosamide Monograph,https://www.drugs.com/monograph/lacosamide.html,BE0003536
L12789,FDA Approved Drug Products: Actemra Tocilizumab Intravenous or Subcutaneous Injection,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125276s127,125472s040lbl.pdf",BE0002638
L7694,FDA Approved Drug Products: Levocetirizine Dihydrochloride Tablets and Oral Solution,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022064s038,022157s020lbl.pdf",BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L2922,OLYSIO (simeprevir) capsules - FDA,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205123s012lbl.pdf,BE0002433
L9764,FDA table of interactions,https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L4163,Intelence (Etravirine) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022187s008lbl.pdf,BE0002638
L4594,Theophylline metabolic pathway,https://www.pharmgkb.org/pathway/PA165958541,BE0002433
L4604,Get to Know an Enzyme: CYP1A2,https://www.pharmacytimes.com/publications/issue/2007/2007-11/2007-11-8279,BE0002433
L4093,INLYTA® (axitinib) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf,BE0002638
L4093,INLYTA® (axitinib) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf,BE0002362
L4093,INLYTA® (axitinib) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf,BE0003536
L4093,INLYTA® (axitinib) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202324lbl.pdf,BE0003541
L4091,CRESEMBA® (isavuconazonium sulfate) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf,BE0002638
L212,Link,http://www.page-meeting.org/pdf_assets/2259-posterPAGE2008_SP.pdf,BE0002363
L8321,"COARTEM® (artemether and lumefantrine) tablets, for oral use - FDA Label",https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/coartem.pdf,BE0003549
L8321,"COARTEM® (artemether and lumefantrine) tablets, for oral use - FDA Label",https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/coartem.pdf,BE0002793
L8321,"COARTEM® (artemether and lumefantrine) tablets, for oral use - FDA Label",https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/coartem.pdf,BE0003536
L4357,Pfizer Pristiq,https://www.pfizermedicalinformation.ca/en-ca/pristiq/drug-interactions#,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L167,JEVTANA - cabazitaxel,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,BE0002638
L167,JEVTANA - cabazitaxel,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,BE0002362
L167,JEVTANA - cabazitaxel,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa,BE0002887
L1838,Copper,https://www.canada.ca/en/health-canada/services/publications/healthy-living/guidelines-canadian-drinking-water-quality-guideline-technical-document-copper.html,BE0000753
L1838,Copper,https://www.canada.ca/en/health-canada/services/publications/healthy-living/guidelines-canadian-drinking-water-quality-guideline-technical-document-copper.html,BE0008684
L1838,Copper,https://www.canada.ca/en/health-canada/services/publications/healthy-living/guidelines-canadian-drinking-water-quality-guideline-technical-document-copper.html,BE0000335
L3849,NCI/NIH,https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C47552&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null,BE0002638
L11067,EMA Summary of Product Characteristics: Dynastat (parecoxib) oral tablets,https://www.ema.europa.eu/en/documents/product-information/dynastat-epar-product-information_en.pdf,BE0002638
L11067,EMA Summary of Product Characteristics: Dynastat (parecoxib) oral tablets,https://www.ema.europa.eu/en/documents/product-information/dynastat-epar-product-information_en.pdf,BE0002793
L3990,Online Health,http://pastande.org/diet-drug-porfimer-sodium-safe-effective-study-finds/,BE0002638
L3686,Lurasidone HCl FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603lbls10s11.pdf,BE0002638
L14201,FDA Approved Drug Products: Brilinta Ticagrelor Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022433s028lbl.pdf,BE0002638
L6979,FDA Approved Drug Products: Kalydeco (ivacaftor),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203188s029,207925s008lbl.pdf",BE0002638
L6979,FDA Approved Drug Products: Kalydeco (ivacaftor),"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203188s029,207925s008lbl.pdf",BE0002362
L4089,Xalkori (Crizotinib) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202570s021lbl.pdf,BE0002638
L4089,Xalkori (Crizotinib) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202570s021lbl.pdf,BE0002362
L12651,FDA Approved Products: Gilenya (fingolimod) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022527s031lbl.pdf,BE0004728
L12690,European Medicines Agency Public Assessment Report: Gilenya (fingolimod),https://www.ema.europa.eu/en/documents/assessment-report/gilenya-epar-public-assessment-report_en.pdf,BE0003533
L12651,FDA Approved Products: Gilenya (fingolimod) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022527s031lbl.pdf,BE0004727
L1742,Cancer Care Ontario Formulary,https://www.cancercareontario.ca/sites/ccocancercare/files/brentuximab%20vedotin.pdf,BE0002638
L3473,FDA Approved Drug Products: VICTRELIS (boceprevir) Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L4083,Fycompa (Perampanel) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf,BE0002638
L4083,Fycompa (Perampanel) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf,BE0002362
L4083,Fycompa (Perampanel) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf,BE0003549
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002363
L9764,FDA table of interactions,https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers,BE0002638
L10196,Enzalutamide FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf,BE0002638
L9764,FDA table of interactions,https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers,BE0002362
L3844,Blog,http://sbolot.org/drug-results-for-formestane-chloride/,BE0002638
L3868,FDA reports,https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM421134.pdf,BE0002638
L3868,FDA reports,https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM421134.pdf,BE0002887
L10181,Dabrafenib FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202806s006lbl.pdf,BE0002638
L2916,luliconazole - Drug Summary PDR,http://www.pdr.net/drug-summary/Luzu-luliconazole-3401,BE0002638
L2916,luliconazole - Drug Summary PDR,http://www.pdr.net/drug-summary/Luzu-luliconazole-3401,BE0003536
L13994,FDA Approved Products: Tekturna (Aliskiren) oral tablets and pellets,https://www.tekturna.com/wp-content/uploads/2017/11/Tekturna_PCR-1.pdf,BE0002638
L13688,FDA Approved Drug Products: Jardiance (empagliflozin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf,BE0003679
L13688,FDA Approved Drug Products: Jardiance (empagliflozin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf,BE0003677
L13688,FDA Approved Drug Products: Jardiance (empagliflozin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf,BE0003682
L13688,FDA Approved Drug Products: Jardiance (empagliflozin) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204629s023lbl.pdf,BE0003538
L11232,FDA Approved Products: Sivextro (tedizolid phosphate) tablet and injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf,BE0002198
L11232,FDA Approved Products: Sivextro (tedizolid phosphate) tablet and injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf,BE0002196
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L4513,FDA reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206545Orig1s000ClinPharmR.pdf,BE0002638
L2942,Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medications,https://academic.oup.com/jac/article/71/7/1755/1750409,BE0002363
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L3432,Cobicistat FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203094s008lbl.pdf,BE0002638
L4063,Brintellix (Vortioxetine) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf,BE0002363
L4063,Brintellix (Vortioxetine) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf,BE0002638
L4063,Brintellix (Vortioxetine) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf,BE0002362
L4063,Brintellix (Vortioxetine) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf,BE0003536
L4063,Brintellix (Vortioxetine) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf,BE0002793
L4063,Brintellix (Vortioxetine) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf,BE0003336
L4063,Brintellix (Vortioxetine) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf,BE0002887
L4063,Brintellix (Vortioxetine) FDA Label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf,BE0003549
L1879,Tibolone: A Unique Version of Hormone Replacement Therapy,http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.919.2384&rep=rep1&type=pdf,BE0001197
L1879,Tibolone: A Unique Version of Hormone Replacement Therapy,http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.919.2384&rep=rep1&type=pdf,BE0000051
L1879,Tibolone: A Unique Version of Hormone Replacement Therapy,http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.919.2384&rep=rep1&type=pdf,BE0000059
L1881,Cardiovascular Effects of Tibolone: A Selective Tissue Estrogenic Activity Regulator,https://onlinelibrary.wiley.com/doi/full/10.1111/j.1527-3466.2007.00007.x,BE0000927
L8453,FDA Approved Drugs: Nintedanib,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205832s010lbl.pdf,BE0003541
L8453,FDA Approved Drugs: Nintedanib,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205832s010lbl.pdf,BE0004695
L8453,FDA Approved Drugs: Nintedanib,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205832s010lbl.pdf,BE0003682
L8453,FDA Approved Drugs: Nintedanib,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205832s010lbl.pdf,BE0003678
L8453,FDA Approved Drugs: Nintedanib,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205832s010lbl.pdf,BE0002638
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L880,European Medicines Agency (EMA): DIACOMIT Summary of Product Characteristics,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf,BE0003536
L880,European Medicines Agency (EMA): DIACOMIT Summary of Product Characteristics,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf,BE0002363
L880,European Medicines Agency (EMA): DIACOMIT Summary of Product Characteristics,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf,BE0002638
L4524,"Eslicarbazepine, PDR",http://m.pdr.net/drug-summary/Aptiom-eslicarbazepine-acetate-3400,BE0003536
L4565,APTIOM ® (eslicarbazepine acetate,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf,BE0003541
L877,Sanofi Canada: ZUACTA (zucapsaicin cream) product monograph,http://products.sanofi.ca/en/zuacta.pdf,BE0002433
L877,Sanofi Canada: ZUACTA (zucapsaicin cream) product monograph,http://products.sanofi.ca/en/zuacta.pdf,BE0003533
L931,Bayer Inc: VISANNE (2mg dienogest tablets) Product Monograph,http://www.bayer.ca/static/documents/news/en/VISANNE-PM-EN-19JUN2015-182736.pdf,BE0002638
L884,World Health Organization: Etizolam (INN) Pre-Review Report ,https://erowid.org/pharms/etizolam/etizolam_article1_who_2016.pdf,BE0002638
L884,World Health Organization: Etizolam (INN) Pre-Review Report ,https://erowid.org/pharms/etizolam/etizolam_article1_who_2016.pdf,BE0003611
L1178,Jstage,https://www.jstage.jst.go.jp/article/jsma1939/45/6/45_6_739/_pdf,BE0002180
L1178,Jstage,https://www.jstage.jst.go.jp/article/jsma1939/45/6/45_6_739/_pdf,BE0004866
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002793
L1308,NCI dictionary,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/polaprezinc,BE0002390
L1308,NCI dictionary,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/polaprezinc,BE0000735
L1308,NCI dictionary,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/polaprezinc,BE0004453
L1308,NCI dictionary,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/polaprezinc,BE0000818
L1308,NCI dictionary,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/polaprezinc,BE0000816
L1308,NCI dictionary,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/polaprezinc,BE0005844
L1308,NCI dictionary,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/polaprezinc,BE0000907
L1341,Zotepine monograph,http://www.drugfuture.com/mt/zotepine.pdf,BE0002638
L1342,KEGG,http://www.genome.jp/dbget-bin/www_bget?D01562,BE0002638
L1379,DRUG: Azelnidipine,http://www.genome.jp/dbget-bin/www_bget?D01145,BE0002638
L1442,Pharmacokinetic Interaction between Warfarin and Efonidipine in Rats,https://pdfs.semanticscholar.org/058d/a3935a5736ea1244a3b6f2e1a6348c792146.pdf,BE0002638
L1126,Lacidipine Summary of Product Characteristics,http://mri.cts-mrp.eu/download/NL_H_2992_002_FinalSPC.pdf,BE0002638
L1490,Amlodipine Metabolism in Human Liver Microsomes and Roles of CYP3A4/5 in the Dihydropyridine Dehydrogenation,http://dmd.aspetjournals.org/content/42/2/245,BE0002638
L3675,"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf,BE0003544
L3675,"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf,BE0003538
L3675,"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf,BE0002433
L12513,In Vitro Assessment of Methylene Blue Hydrate as a Multiple CYP450 Inhibitor and a Mechanism-Based Inhibitor,https://www.researchgate.net/publication/268145483_In_Vitro_Assessment_of_Methylene_Blue_Hydrate_as_a_Multiple_CYP450_Inhibitor_and_a_Mechanism-Based_Inhibitor,BE0002433
L12513,In Vitro Assessment of Methylene Blue Hydrate as a Multiple CYP450 Inhibitor and a Mechanism-Based Inhibitor,https://www.researchgate.net/publication/268145483_In_Vitro_Assessment_of_Methylene_Blue_Hydrate_as_a_Multiple_CYP450_Inhibitor_and_a_Mechanism-Based_Inhibitor,BE0003549
L3675,"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf,BE0003549
L12153,NIH StatPearls: Cholesterol levels,https://www.ncbi.nlm.nih.gov/books/NBK542294/,BE0002887
L3675,"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf,BE0002887
L12153,NIH StatPearls: Cholesterol levels,https://www.ncbi.nlm.nih.gov/books/NBK542294/,BE0002793
L3675,"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf,BE0002793
L12153,NIH StatPearls: Cholesterol levels,https://www.ncbi.nlm.nih.gov/books/NBK542294/,BE0003536
L3675,"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf,BE0003536
L12153,NIH StatPearls: Cholesterol levels,https://www.ncbi.nlm.nih.gov/books/NBK542294/,BE0002638
L3675,"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf,BE0002638
L12153,NIH StatPearls: Cholesterol levels,https://www.ncbi.nlm.nih.gov/books/NBK542294/,BE0002362
L3675,"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf,BE0002362
L3675,"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf,BE0000595
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002363
L3675,"FDA Approved Drug Products: PROVAYBLUE (methylene blue) injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204630s000lbl.pdf,BE0002363
L1389,Tolaxatone,http://www.mims.com/india/drug/info/toloxatone?mtype=generic,BE0002198
L934,UFT (uracil/tegafur) capsules_Product information,https://hemonc.org/docs/packageinsert/uraciltegafur.pdf,BE0003336
L1065,Coenzyme Q,http://fodsupport.org/pdf/Description_of_CoQ_10.pdf,BE0000574
L4594,Theophylline metabolic pathway,https://www.pharmgkb.org/pathway/PA165958541,BE0002433
L14099,FDA Approved Drug Products: Artesunate Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf,BE0003679
L14099,FDA Approved Drug Products: Artesunate Intravenous Injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf,BE0003538
L891,Artesunate Product Information,https://extranet.who.int/prequal/sites/default/files/documents/MA051part4v2.pdf,BE0003336
L1496,A gastroprotective anti-inflammatory agent: theβ-morpholinoethyl ester of niflumic acid (morniflumate),https://www.researchgate.net/publication/16587181_A_gastroprotective_anti-inflammatory_agent_theb-morpholinoethyl_ester_of_niflumic_acid_morniflumate,BE0000248
L1496,A gastroprotective anti-inflammatory agent: theβ-morpholinoethyl ester of niflumic acid (morniflumate),https://www.researchgate.net/publication/16587181_A_gastroprotective_anti-inflammatory_agent_theb-morpholinoethyl_ester_of_niflumic_acid_morniflumate,BE0000262
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002433
L1405,TALNIFLUMATE,https://drugs.ncats.io/ginas/app/substance/7c324c44,BE0000017
L1405,TALNIFLUMATE,https://drugs.ncats.io/ginas/app/substance/7c324c44,BE0000262
L6277,"FDA Approved Drug Products: Bictegravir, Emtricitabine, and Tenofovir Alafenamide Oral Tablets",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf,BE0002638
L1536,Metafishnet,http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png,BE0000972
L1536,Metafishnet,http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png,BE0001153
L1536,Metafishnet,http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png,BE0000883
L1536,Metafishnet,http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png,BE0009328
L1536,Metafishnet,http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png,BE0009329
L1536,Metafishnet,http://mummichog.org/shuzhao/mfn1.9/humanpngs2/mfn1v9path123.png,BE0009330
L430,DAILYMED,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a03fe85-fdc9-4847-960f-1fc782d7d493,BE0000896
L934,UFT (uracil/tegafur) capsules_Product information,https://hemonc.org/docs/packageinsert/uraciltegafur.pdf,BE0003336
L1557,National Cancer Institute,https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tegafur-uracil,BE0000960
L1503,"Pharmacokinetics Basics- Absorption, Distribution, Metabolism and Excretion",https://www.ndrugs.com/?s=vayarin&t=actions,BE0003533
L1508,"Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of  EPA, DPA and DHA",https://www.frontiersin.org/articles/10.3389/fnagi.2015.00052/,BE0000888
L1506,Vayarin product label,https://vayadirect.com/wp-content/uploads/2018/01/RIN_PI_PA-Final_new-slip.pdf,BE0002247
L1568,Vitamin K metabolism,http://smpdb.ca/view/SMP00464,BE0000713
L1561,Menadiol Sodium Pharmacology,https://www.ndrugs.com/?s=creatinine%20sulfate/esculoside/hesperidin%20methyl%20chalcone/menadiol%20sodium%20phosphate/tranexamic%20acid&t=actions#doctor_pharmacology,BE0002364
L1586,Metabolic adaptation of renal carbohydrate metabolism. V.In vivo response of rat renal-tubule gluconeogenesis to different diuretics,https://link.springer.com/article/10.1007/BF00944073,BE0000906
L1606,Foreign Compound Metabolism in Mammals,https://books.google.ca/books?id=raKIFKRdi0AC&pg=PA423&lpg=PA423&dq=tyropanoic+acid&source=bl&ots=qASeCBztrt&sig=Ux3ZzP6AIeG9EQyKiq90uLdTUh8&hl=en&sa=X&ved=0ahUKEwjMs9PgjuDZAhUE6mMKHY3qA404ChDoAQhBMAY#v=onepage&q=tyropanoic%20acid&f=false,BE0000972
L1592,Handbook of Dental Anesthesia- Ebook,https://books.google.ca/books?id=3MfsAwAAQBAJ&pg=PA57&lpg=PA57&dq=dental+anesthetic+propoxycaine&source=bl&ots=83RGmRB2vJ&sig=EQcChwt3P5m2LM5yto8r8a5C-GI&hl=en&sa=X&ved=0ahUKEwjVt6-D1t_ZAhUB_2MKHaM4A6cQ6AEITTAD#v=onepage&q=dental%20anesthetic%20propoxycaine&f=false,BE0002705
L1618,Review of Rauwolfia,https://www.sciencedirect.com/topics/medicine-and-dentistry/rauvolfia-serpentina,BE0004909
L465,UniProt,http://www.uniprot.org/uniprot/O75874,BE0001251
L464,ChEMBL,https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1646,BE0001251
L466,UniProt,http://www.uniprot.org/uniprot/O94925,BE0000825
L464,ChEMBL,https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1646,BE0000825
L3840,NCI/NIH,https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C65730&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null,BE0002638
L3853,NCI/NIH,https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C66096&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null,BE0002638
L328,article,http://jn.nutrition.org/content/137/7/1750.full,BE0000350
L473,UniProt,http://www.uniprot.org/uniprot/P19111,BE0008244
L474,CHEMbl,https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1200925,BE0008244
L490,UniProt,http://www.uniprot.org/uniprot/Q9P2W7,BE0001242
L491,UniProt,http://www.uniprot.org/uniprot/Q9NWT6,BE0002503
L489,HMDB,http://www.hmdb.ca/metabolites/HMDB29878,BE0002503
L2401,FDA reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205060Orig1s000PharmR.pdf,BE0004866
L2401,FDA reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205060Orig1s000PharmR.pdf,BE0004727
L558,UniProt,http://www.uniprot.org/uniprot/P10938,BE0000865
L559,ChEMBL,https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL19393,BE0000865
L1790,PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies,http://dmd.aspetjournals.org/content/dmd/35/1/9.full.pdf,BE0000421
L1790,PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies,http://dmd.aspetjournals.org/content/dmd/35/1/9.full.pdf,BE0000009
L1790,PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies,http://dmd.aspetjournals.org/content/dmd/35/1/9.full.pdf,BE0000927
L1764,Dietary nitrite and nitrate: a review of potential mechanisms of cardiovascular benefits,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489477/,BE0002499
L2023,HYDROGEN PEROXIDE - National Library of Medicine HSDB ... - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+547,BE0000816
L2024,Chemical Summary for Hydrogen Peroxide - SSWM,https://www.sswm.info/sites/default/files/reference_attachments/OAK%20RIDGE%20NATIONAL%20LABORATORY%201995%20Chemical%20Summary%20of%20Hydrogen%20Peroxide.pdf,BE0000816
L2023,HYDROGEN PEROXIDE - National Library of Medicine HSDB ... - Toxnet,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+547,BE0001207
L2024,Chemical Summary for Hydrogen Peroxide - SSWM,https://www.sswm.info/sites/default/files/reference_attachments/OAK%20RIDGE%20NATIONAL%20LABORATORY%201995%20Chemical%20Summary%20of%20Hydrogen%20Peroxide.pdf,BE0001207
L2033,Ammonia - National Library of Medicine HSDB Database - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+162,BE0000003
L2033,Ammonia - National Library of Medicine HSDB Database - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+162,BE0002240
L2033,Ammonia - National Library of Medicine HSDB Database - Toxnet - NIH,https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+162,BE0004671
L1914,High-dose selenium for critically ill patients with systemic inflammation: Pharmacokinetics and pharmacodynamics of selenious acid: A pilot study,http://www.nutritionjrnl.com/article/S0899-9007(09)00297-4/pdf,BE0000816
L1807,Health partners,https://www.healthpartners.com/ucm/groups/public/@hp/@public/@ime/@content/documents/documents/cntrb_031044.pdf,BE0002363
L2684,"Effects of triclocarban on the transcription of estrogen, androgen and aryl hydrocarbon receptor responsive genes in human breast cancer cells",https://www.sciencedirect.com/science/article/pii/S0887233313000672,BE0003543
L2684,"Effects of triclocarban on the transcription of estrogen, androgen and aryl hydrocarbon receptor responsive genes in human breast cancer cells",https://www.sciencedirect.com/science/article/pii/S0887233313000672,BE0001111
L4604,Get to Know an Enzyme: CYP1A2,https://www.pharmacytimes.com/publications/issue/2007/2007-11/2007-11-8279,BE0002433
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L9776,Lesinurad FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207988lbl.pdf,BE0002638
L10253,Zepatier FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208261s002lbl.pdf,BE0002638
L2293,Australian Public Assessment Report: Asunaprevir,https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf,BE0002638
L2287,Australian Product Information: Sunvepra (Asunaprevir) Capsules,http://www.medicines.org.au/files/bqpsunve.pdf,BE0002638
L2293,Australian Public Assessment Report: Asunaprevir,https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf,BE0002362
L2287,Australian Product Information: Sunvepra (Asunaprevir) Capsules,http://www.medicines.org.au/files/bqpsunve.pdf,BE0002362
L2293,Australian Public Assessment Report: Asunaprevir,https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf,BE0003336
L2293,Australian Public Assessment Report: Asunaprevir,https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf,BE0003549
L2293,Australian Public Assessment Report: Asunaprevir,https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf,BE0002793
L2293,Australian Public Assessment Report: Asunaprevir,https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf,BE0003536
L2293,Australian Public Assessment Report: Asunaprevir,https://www.tga.gov.au/sites/default/files/auspar-asunaprevir-151214.pdf,BE0002363
L2287,Australian Product Information: Sunvepra (Asunaprevir) Capsules,http://www.medicines.org.au/files/bqpsunve.pdf,BE0002363
L769,FDA Clinical Pharmacology and Biopharmaceutics Review,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000ClinPharmR.pdf,BE0002793
L2341,EMA assessment report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002790/WC500209538.pdf,BE0003536
L2341,EMA assessment report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002790/WC500209538.pdf,BE0002887
L2385,α-TOCOPHEROL β-OXIDATION LOCALIZED TO RAT LIVER MITOCHONDRIA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818260/,BE0004727
L2384,Vitamin E Regulatory Mechanisms,https://www.annualreviews.org/doi/abs/10.1146/annurev.nutr.27.061406.093819,BE0004727
L8528,Vitamin E,https://epdf.pub/vitamin-e-a-medical-dictionary-bibliography-and-annotated-research-guide-to-inte.html,BE0004727
L1407,"Deltyba, INN-Delamanid - European Medicines Agency - Europa EU",http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002552/WC500166232.pdf,BE0002638
L1149,EMA: Eurartesim Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf,BE0003538
L1149,EMA: Eurartesim Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf,BE0003679
L1149,EMA: Eurartesim Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf,BE0002363
L1149,EMA: Eurartesim Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf,BE0003536
L12945,FDA approved products: Tukysa (tucatinib) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf,BE0002887
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0004866
L12945,FDA approved products: Tukysa (tucatinib) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf,BE0004866
L12945,FDA approved products: Tukysa (tucatinib) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf,BE0000511
L12852,FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf,BE0002638
L12852,FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf,BE0002793
L12852,FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf,BE0002433
L12852,FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf,BE0003533
L12852,FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf,BE0002362
L12852,FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf,BE0003541
L12852,FDA Approved Drug Products: Koselugo (selumetinib) capsules for oral use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213756s000lbl.pdf,BE0003677
L10241,FDA Approved Drug Products: Calquence Acalabrutinib Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf,BE0002638
L10241,FDA Approved Drug Products: Calquence Acalabrutinib Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf,BE0002362
L10241,FDA Approved Drug Products: Calquence Acalabrutinib Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf,BE0004866
L6814,Symdeko FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf,BE0002638
L6829,"Monograph, Tezacaftor/Ivacaftor",https://pdf.hres.ca/dpd_pm/00046145.PDF,BE0002638
L6814,Symdeko FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210491lbl.pdf,BE0002362
L6829,"Monograph, Tezacaftor/Ivacaftor",https://pdf.hres.ca/dpd_pm/00046145.PDF,BE0002362
L9338,FDA Approved Drugs: Reyvow,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf,BE0002363
L8558,FDA Approved Drugs: Tenapanor,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf,BE0002638
L8558,FDA Approved Drugs: Tenapanor,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf,BE0002362
L1000,ema.europa,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004254/WC500230070.pdf,BE0002638
L4281,Book section,https://dokumen.tips/documents/drug-interactions-in-infectious-diseases-quinolones.html,BE0002433
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L13347,FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf,BE0002638
L13347,FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf,BE0003539
L13347,FDA Approved Drug Products: Tabrecta (capmatinib) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf,BE0002433
L12123,FDA Approved Drug Products: Isturisa (osilodrostat) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf,BE0002638
L12132,EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets,https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf,BE0002638
L12123,FDA Approved Drug Products: Isturisa (osilodrostat) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf,BE0003549
L12132,EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets,https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf,BE0003549
L12123,FDA Approved Drug Products: Isturisa (osilodrostat) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf,BE0002363
L12132,EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets,https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf,BE0002363
L12132,EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets,https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf,BE0003544
L12132,EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets,https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf,BE0003679
L12132,EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets,https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf,BE0009343
L12132,EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets,https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf,BE0002362
L12123,FDA Approved Drug Products: Isturisa (osilodrostat) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf,BE0002433
L12123,FDA Approved Drug Products: Isturisa (osilodrostat) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf,BE0003536
L12132,EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets,https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf,BE0003533
L12132,EMA Summary of Product Characteristics: Isturisa (osilodrostat) oral tablets,https://www.ema.europa.eu/en/documents/product-information/isturisa-epar-product-information_en.pdf,BE0008629
L5942,Pfam Aldo/Keto Reductase Family Profile,http://pfam.xfam.org/family/PF00248,BE0000747
L6700,Deflazacort FDA label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208684s003,208685s003lbl.pdf",BE0002638
L12144,FDA Approved Products: Nexletol (bempedoic acid) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf,BE0009868
L12147,Bempedoic acid: A novel agent (Esperion),https://www.esperion.com/science/bempedoic-acid/,BE0009868
L12144,FDA Approved Products: Nexletol (bempedoic acid) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf,BE0003679
L12144,FDA Approved Products: Nexletol (bempedoic acid) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf,BE0000350
L9770,Delafloxacin FDA label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf",BE0002638
L10863,FDA Approved Drug Products: Dayvigo (lemborexant) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf,BE0002638
L10863,FDA Approved Drug Products: Dayvigo (lemborexant) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf,BE0002362
L10863,FDA Approved Drug Products: Dayvigo (lemborexant) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf,BE0003549
L10863,FDA Approved Drug Products: Dayvigo (lemborexant) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf,BE0004866
L8081,FDA Label: Rozlytrek,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf,BE0002638
L6655,New Mexico Cancer Alliance: Compassionate Use of Alpelisib,https://clinicaltrials.gov/ProvidedDocs/82/NCT03941782/Prot_000.pdf,BE0002638
L6655,New Mexico Cancer Alliance: Compassionate Use of Alpelisib,https://clinicaltrials.gov/ProvidedDocs/82/NCT03941782/Prot_000.pdf,BE0002793
L6655,New Mexico Cancer Alliance: Compassionate Use of Alpelisib,https://clinicaltrials.gov/ProvidedDocs/82/NCT03941782/Prot_000.pdf,BE0002887
L6655,New Mexico Cancer Alliance: Compassionate Use of Alpelisib,https://clinicaltrials.gov/ProvidedDocs/82/NCT03941782/Prot_000.pdf,BE0003536
L8531,FDA Approved Drug Products: Tpoxx (tecovirimat) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208627s000lbl.pdf,BE0003541
L8531,FDA Approved Drug Products: Tpoxx (tecovirimat) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208627s000lbl.pdf,BE0003544
L4835,Clinical trials,https://clinicaltrials.gov/ct2/show/NCT02456883,BE0002638
L8534,Polotuzumab FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf,BE0002638
L1028,FDA Reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf,BE0002887
L1028,FDA Reports,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf,BE0002638
L2315,Mictoryl monograph,https://www.duchesnay.com/files/pdf/mictoryl-monograph.pdf,BE0002638
L12729,FDA Approved Drug Products: Pifeltro (doravirine) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210806s003lbl.pdf,BE0002638
L12729,FDA Approved Drug Products: Pifeltro (doravirine) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210806s003lbl.pdf,BE0002362
L4551,Eravacycline,https://www.drugs.com/ppa/eravacycline.html,BE0002638
L2920,Rucaparib - Drug Summary Prescribers Digital Reference,http://www.pdr.net/drug-summary/Rubraca-rucaparib-23992,BE0002433
L2920,Rucaparib - Drug Summary Prescribers Digital Reference,http://www.pdr.net/drug-summary/Rubraca-rucaparib-23992,BE0002638
L344,Daily med.,https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6d46c03-bb1d-417b-b8e5-3bffe352fe29,BE0002793
L4652,EMA Reports,https://www.ema.europa.eu/documents/product-information/rubraca-epar-product-information_en.pdf,BE0002793
L4653,Rubraca,https://www.rubracahcp.com/,BE0002793
L4594,Theophylline metabolic pathway,https://www.pharmgkb.org/pathway/PA165958541,BE0002433
L11971,FDA Approved Drug Products: Nurtec ODT (rimegepant) orally disintegrating tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf,BE0002638
L11971,FDA Approved Drug Products: Nurtec ODT (rimegepant) orally disintegrating tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf,BE0002793
L12075,Pharmaceuticals and Medical Devices Agency: Avigan (favipiravir) Review Report,https://www.pmda.go.jp/files/000210319.pdf,BE0003533
L8090,FDA Approved Drug Products: Fedratinib Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf,BE0002638
L8090,FDA Approved Drug Products: Fedratinib Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf,BE0003536
L8090,FDA Approved Drug Products: Fedratinib Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf,BE0003606
L8090,FDA Approved Drug Products: Fedratinib Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf,BE0002363
L7538,Interactions of the H1 antihistamines,http://www.jiaci.org/issues/vol16s1/5.pdf,BE0002363
L12582,FDA Approved Products: Zeposia (Ozanimod) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf,BE0000600
L12582,FDA Approved Products: Zeposia (Ozanimod) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf,BE0000009
L12582,FDA Approved Products: Zeposia (Ozanimod) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf,BE0003607
L12582,FDA Approved Products: Zeposia (Ozanimod) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf,BE0002887
L12582,FDA Approved Products: Zeposia (Ozanimod) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf,BE0002196
L12582,FDA Approved Products: Zeposia (Ozanimod) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf,BE0000126
L12582,FDA Approved Products: Zeposia (Ozanimod) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf,BE0000622
L12582,FDA Approved Products: Zeposia (Ozanimod) oral capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf,BE0002638
L14327,FDA Approved Drug Products: Zepzelca (lurbinectedin) for intravenous injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf,BE0002638
L9013,FDA Approved Drugs: Aklief®,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf,BE0002793
L9013,FDA Approved Drugs: Aklief®,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf,BE0002638
L9013,FDA Approved Drugs: Aklief®,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf,BE0002887
L9013,FDA Approved Drugs: Aklief®,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf,BE0003549
L8093,Xenleta FDA label,"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf",BE0002638
L11476,FDA Approved Drug Products: Tazverik Tazemetostat Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211723s000lbl.pdf,BE0004866
L13002,FDA Approved Drug Products: Trodelvy (sacituzumab govitecan-hziy) injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761115s000lbl.pdf,BE0003541
L10872,"FDA Approved Drug Products: NUBEQA (darolutamide) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf,BE0002638
L10872,"FDA Approved Drug Products: NUBEQA (darolutamide) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf,BE0003538
L8426,DEPO-MEDROL® (methylprednisolone acetate injectable suspension USP) - Product Monograph,https://www.pfizer.ca/sites/default/files/201805/DEPO-MEDROL_PM_E_213592_3May2018.pdf,BE0002638
L7883,FDA Approved Drug Products: Turaliotm (pexidartinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf,BE0002638
L7883,FDA Approved Drug Products: Turaliotm (pexidartinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf,BE0003544
L7883,FDA Approved Drug Products: Turaliotm (pexidartinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf,BE0003549
L7883,FDA Approved Drug Products: Turaliotm (pexidartinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf,BE0002793
L7883,FDA Approved Drug Products: Turaliotm (pexidartinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf,BE0003541
L10836,FDA Approved Drug Products: Padcev (enfortumab vedotin-ejfv) for IV injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003549
L571,UniProt,http://www.uniprot.org/uniprot/P08684,BE0002638
L572,ChEMBL,https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1002,BE0002638
L524,ChEMBL,https://www.ebi.ac.uk/chembl/target/results/keyword,BE0002363
L573,KEGG,http://www.kegg.jp/dbget-bin/www_bget?dr:D08124,BE0002363
L575,CHEMbl,https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1624854,BE0000825
L466,UniProt,http://www.uniprot.org/uniprot/O94925,BE0000825
L576,KEGG,http://www.genome.jp/dbget-bin/www_bget?cpd:C09264,BE0000825
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002362
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0002638
L2905,Drug Interactions & Labeling - FDA,https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2,BE0003612
L4594,Theophylline metabolic pathway,https://www.pharmgkb.org/pathway/PA165958541,BE0002433
L3857,NCI/NIH,https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C80268&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null,BE0002638
L1825,The Pharmacokinetics  and Pharmacodynamics of Iron Preparations,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857035/,BE0001140
L11794,"NIH Statpearls: Biochemistry, Iron Absorption",https://www.ncbi.nlm.nih.gov/books/NBK448204/,BE0009858
L11794,"NIH Statpearls: Biochemistry, Iron Absorption",https://www.ncbi.nlm.nih.gov/books/NBK448204/,BE0000510
L11794,"NIH Statpearls: Biochemistry, Iron Absorption",https://www.ncbi.nlm.nih.gov/books/NBK448204/,BE0008687
L11794,"NIH Statpearls: Biochemistry, Iron Absorption",https://www.ncbi.nlm.nih.gov/books/NBK448204/,BE0009859
L4594,Theophylline metabolic pathway,https://www.pharmgkb.org/pathway/PA165958541,BE0002433
L4594,Theophylline metabolic pathway,https://www.pharmgkb.org/pathway/PA165958541,BE0002433
L4594,Theophylline metabolic pathway,https://www.pharmgkb.org/pathway/PA165958541,BE0002433
L2655,Potassium Supplements (Systemic),https://www.drugs.com/mmx/potassium-gluconate-and-potassium-chloride.html,BE0000229
L4594,Theophylline metabolic pathway,https://www.pharmgkb.org/pathway/PA165958541,BE0002433
L12849,FDA Approved Drug Products: Fluorodopa F18 injection for intravenous use,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/200655s000lbl.pdf,BE0002151
L3826,Gene labs,http://genelabs.com/drugsdb/details/ethynodiol-diacetate/,BE0002638
L3842,NCI/NIH,https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C61767&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null,BE0002638
L3868,FDA reports,https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM421134.pdf,BE0002638
L3868,FDA reports,https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM421134.pdf,BE0002887
L10259,FDA Approved Drug Products: Mavyrettm (glecaprevir and pibrentasvir) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209394s000lbl.pdf,BE0004866
L10250,Glecaprevir FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209394s006lbl.pdf,BE0002638
L2883,Uniprot PDE3,http://www.uniprot.org/uniprot/J3SEZ3,BE0000457
L1069,FDA Reports,https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM580460.pdf,BE0000239
L1069,FDA Reports,https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM580460.pdf,BE0001671
L1149,EMA: Eurartesim Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf,BE0002638
L1149,EMA: Eurartesim Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf,BE0003536
L1149,EMA: Eurartesim Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf,BE0002793
L1149,EMA: Eurartesim Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf,BE0003549
L1149,EMA: Eurartesim Assessment Report,http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf,BE0003533
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L81,Source,http://www.currentseparations.com/issues/20-3/20-3d.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L1153,Pfizer monograph,https://www.pfizer.ca/sites/g/files/g10028126/f/201601/DepoTestosterone_PM_189981_15Jan2016_E.pdf,BE0004887
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L81,Source,http://www.currentseparations.com/issues/20-3/20-3d.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L1153,Pfizer monograph,https://www.pfizer.ca/sites/g/files/g10028126/f/201601/DepoTestosterone_PM_189981_15Jan2016_E.pdf,BE0004887
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L81,Source,http://www.currentseparations.com/issues/20-3/20-3d.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L2310,Isolation of CYP3A4 Inhibitors from the Black Cohosh (Cimicifuga racemosa),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1142198/,BE0002638
L2311,Cytochrome P450 enzyme mediated herbal drug interactions (Part 2),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464477/,BE0004761
L2311,Cytochrome P450 enzyme mediated herbal drug interactions (Part 2),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464477/,BE0002433
L2311,Cytochrome P450 enzyme mediated herbal drug interactions (Part 2),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464477/,BE0002793
L2311,Cytochrome P450 enzyme mediated herbal drug interactions (Part 2),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464477/,BE0002363
L8582,Sativex monograph,https://www.bayer.ca/omr/online/sativex-pm-en.pdf,BE0002363
L4594,Theophylline metabolic pathway,https://www.pharmgkb.org/pathway/PA165958541,BE0002433
L2631,Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/palonosetron) in the United States,https://www.helsinn.com/news-and-events/helsinn-group-announces-the-fda-approval-of-the-iv-formulation-of-akynzeo-fosnetupitant-palonosetron-in-the-united-states/,BE0002638
L6277,"FDA Approved Drug Products: Bictegravir, Emtricitabine, and Tenofovir Alafenamide Oral Tablets",https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210251s000lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002363
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L2210,Zinc metabolism,http://flipper.diff.org/app/pathways/3503,BE0001123
L2210,Zinc metabolism,http://flipper.diff.org/app/pathways/3503,BE0000465
L2210,Zinc metabolism,http://flipper.diff.org/app/pathways/3503,BE0001183
L2210,Zinc metabolism,http://flipper.diff.org/app/pathways/3503,BE0002390
L9926,FDA Approved Drug Products: Auryxia (ferric citrate) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205874s013lbl.pdf,BE0009859
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L11232,FDA Approved Products: Sivextro (tedizolid phosphate) tablet and injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf,BE0002198
L11232,FDA Approved Products: Sivextro (tedizolid phosphate) tablet and injection,https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205435s000lbl.pdf,BE0002196
L4565,APTIOM ® (eslicarbazepine acetate,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf,BE0003541
L4524,"Eslicarbazepine, PDR",http://m.pdr.net/drug-summary/Aptiom-eslicarbazepine-acetate-3400,BE0003536
L4565,APTIOM ® (eslicarbazepine acetate,https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022416s000lbl.pdf,BE0002638
L3840,NCI/NIH,https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C65730&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null,BE0002638
L10184,"Dexamethasone monograph, Boehringer Ingelheim",https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Roxane/Dexamethasone/Dexamethasone%20Tablets%20Solution%20and%20Intensol.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L10710,FDA Approved Drug Products: Hemady Dexamethasone Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211379s000lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002362
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0003612
L11994,FDA Approved Drug Products: Celestone Soluspan (betamethasone sodium phosphate and betamethasone acetate) injectable suspension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/014602s062lbl.pdf,BE0002638
L5083,The Human Metabolome Database: Queuine Profile,http://www.hmdb.ca/metabolites/HMDB0001495,BE0001405
L13239,FDA: Fact Sheet For Health Care Providers EUA of Remdesivir,https://www.fda.gov/media/137566/download,BE0002887
L13239,FDA: Fact Sheet For Health Care Providers EUA of Remdesivir,https://www.fda.gov/media/137566/download,BE0002363
L13239,FDA: Fact Sheet For Health Care Providers EUA of Remdesivir,https://www.fda.gov/media/137566/download,BE0002638
L9623,Vumerity FDA label,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211855s000lbl.pdf,BE0009561
L13769,"FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf,BE0002887
L13769,"FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf,BE0000453
L13769,"FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf,BE0000852
L13769,"FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf,BE0002638
L13769,"FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf,BE0002363
L13769,"FDA Approved Drug Products: QINLOCK (ripretinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf,BE0003533
L10842,"FDA Approved Drug Products: ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf,BE0000971
L10842,"FDA Approved Drug Products: ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761139s000lbl.pdf,BE0002638
L10397,FDA Approved Drug Products: Oxbrytatm (voxelotor) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf,BE0002638
L10397,FDA Approved Drug Products: Oxbrytatm (voxelotor) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf,BE0002793
L10397,FDA Approved Drug Products: Oxbrytatm (voxelotor) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf,BE0003549
L10397,FDA Approved Drug Products: Oxbrytatm (voxelotor) tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf,BE0003536
L10163,FDA Approved Drug Products: Brukinsa (zanubrutinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf,BE0002638
L10163,FDA Approved Drug Products: Brukinsa (zanubrutinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf,BE0003549
L10163,FDA Approved Drug Products: Brukinsa (zanubrutinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf,BE0004866
L10896,"FDA Approved Drug Products: Rinvoq (upadacitinib) extended-release tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf,BE0002638
L10896,"FDA Approved Drug Products: Rinvoq (upadacitinib) extended-release tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf,BE0002363
L13050,"FDA Approved Drug Products: PEMAZYRE (pemigatinib) tablets, for oral use",https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf,BE0002638
L11136,FDA Approved Drug Products: Avapritinib Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf,BE0002638
L11136,FDA Approved Drug Products: Avapritinib Oral Tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf,BE0002793
L10926,FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf,BE0002638
L10926,FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf,BE0002887
L10926,FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf,BE0002793
L10926,FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf,BE0003536
L10926,FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf,BE0002198
L10926,FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf,BE0003541
L10926,FDA Approved Drug Products: Ubrelvy (ubrogepant) oral tablets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf,BE0002363
L9395,"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf,BE0002638
L9395,"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf,BE0002362
L9395,"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf,BE0002433
L9395,"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf,BE0003549
L9395,"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf,BE0002887
L9395,"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf,BE0002793
L9395,"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf,BE0003536
L9395,"FDA Approved Drug Products: Trikafta (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212273s000lbl.pdf,BE0002363
L10974,FDA Approved Drug Products: Accrufer Ferric Maltol Oral Capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212320Orig1s000lbl.pdf,BE0004694
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002638
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002638
L13604,FDA Approved Drug Products: Retevmo (selpercatinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf,BE0002638
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0002887
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0002887
L13604,FDA Approved Drug Products: Retevmo (selpercatinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf,BE0002887
L162,Flockhart Table of Drug Interactions,https://drug-interactions.medicine.iu.edu/Main-Table.aspx,BE0004866
L2953,"FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers",https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm,BE0004866
L13604,FDA Approved Drug Products: Retevmo (selpercatinib) capsules,https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf,BE0004866
